A Phase I, Open-Label, Multi-Center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 Hyd-Sulfate When Given in Combination with Standard Doses of Selected Chemotherapies to Patients with Advanced Solid Tumors

Trial Profile

A Phase I, Open-Label, Multi-Center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 Hyd-Sulfate When Given in Combination with Standard Doses of Selected Chemotherapies to Patients with Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Selumetinib (Primary) ; Dacarbazine; Docetaxel; Erlotinib; Temsirolimus
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 19 Apr 2017 Results published in the Investigational New Drugs
    • 19 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top